Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | LAP3 | P28838 | 2/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.37 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.36 |
| ▸ | PYGL | P06737 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10074349 | 0.88 | MMP2 (0.50) | MMP2CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL10074145 | 0.88 | MMP2 (0.50) | MMP2CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL10078080 | 0.88 | DPP4 (0.38) | MMP2DPP4DPP7DPP9LAP3 | |
| SCHEMBL10074160 | 0.86 | DPP4 (0.36) | MMP2CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL10074474 | 0.82 | ATM (0.43) | — | |
| SCHEMBL10074341 | 0.82 | ATM (0.43) | — | |
| SCHEMBL10074304 | 0.76 | ATM (0.41) | — | |
| SCHEMBL10077474 | 0.76 | ATM (0.40) | — | |
| SCHEMBL10077078 | 0.75 | LAP3 (0.45) | MMP2DPP4DPP7DPP9LAP3 | |
| SCHEMBL10078089 | 0.75 | LAP3 (0.45) | MMP2DPP4DPP7DPP9LAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418196-A1 | Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors | IMTM GmbH (DE) | 2012-02-15 | — | — | EP | disclosed |
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | IMTM GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | SERPINB1, CMA1, CPA3 | MMP2 17/4885CHRNB2 3717/4885CHRNB4 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.